{"id":"W2593047881","doi":"10.1111/jdv.14211","title":"Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from <scp>UNCOVER</scp>‐2 and <scp>UNCOVER</scp>‐3","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"SKiN Health; Queen's University","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Dermatology Life Quality Index; Post-hoc analysis; Minimal clinically important difference; Clinical endpoint; Placebo; Hazard ratio; Randomization; Randomized controlled trial; Quality of life (healthcare); Internal medicine; Confidence interval; Pathology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008564698,0.001044566,0.003080488,0.0003898998,0.0002966976,0.001408087,0.0004581648,0.000715471,0.00329367],"category_scores_gemma":[0.007105008,0.0003730335,0.006553732,0.0006682306,0.0007425829,0.0008059085,0.0004376023,0.001622049,0.0002460697],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007155938,"about_ca_system_score_gemma":0.001452931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005009032,"about_ca_topic_score_gemma":0.001426632,"domain_scores_codex":[0.9964117,0.002282109,0.0004390792,0.0003302034,0.0003185456,0.0002182596],"domain_scores_gemma":[0.9947768,0.002426307,0.001842511,0.0003151358,0.00030931,0.0003298971],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9122178,0.001990196,0.005475041,0.00526836,0.02260259,0.00005648746,0.0000772503,0.001041332,0.002563972,0.0001399257,0.00140266,0.04716428],"study_design_scores_gemma":[0.8717484,0.07807965,0.02029726,0.0006264194,0.02481481,0.0001447443,0.00006228952,0.0006202907,0.00120652,0.0003361391,0.002021032,0.00004251869],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9280074,0.05996313,0.001853653,0.0009543158,0.0004589701,0.003515794,0.002778975,0.0001379113,0.002329807],"genre_scores_gemma":[0.9758127,0.01528751,0.001853797,0.0006304192,0.0004164247,0.003298588,0.00188893,0.00004250546,0.0007691462],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008564698,"threshold_uncertainty_score":0.045295,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.055895265232394,"score_gpt":0.3162650381622829,"score_spread":0.2603697729298889,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}